Article

Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approach

2023-02-22

Abstract excerpt

Alzheimer’s disease (AD) has no Food and Drug Administration (FDA) approved drugs that can halt neurodegeneration. To halt neurodegeneration, targeting the major pathways underlying in AD might be the potential strategy. One such pathways are Amyloid-β (Aβ) and tau pathways which are majorly regulated by β- amyloid precursor protein cleaving enzyme 1 (BACE1) and Glycogen synthase kinase (GSK-3β) respectively. BACE...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5cf2d294-6b4f-57be-946f-dc7fbeaecfb5
DOI: 10.21203/rs.3.rs-2597691/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approachDOI 10.21203/rs.3.rs-2597691/v1Read

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read

Identification of new BACE1 inhibitors for treating Alzheimer’s diseaseSemantic proximity Read

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s DiseaseSemantic proximity Read

Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In VivoSemantic proximity Read

Identification Mechanism of BACE1 on Inhibitors Probed by Using Multiple Separate Molecular Dynamics Simulations and Comparative Calculations of Binding Free EnergiesSemantic proximity Read

Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.Semantic proximity Read

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentSemantic proximity Read

<strong> </strong> Exploring the Therapeutic Potential of Hypericin: Molecular Docking with ABAD and BACE1 targets in Alzheimer's Disease PathogenesisSemantic proximity Read

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formationSemantic proximity Read

African Natural Products for Multitarget-Based Treatment of Alzheimer’s Disease: An In Silico StudySemantic proximity Read

Machine Learning–Based QSAR Screening of Natural Product and ZINC Libraries Uncovers Stable BACE-1 Inhibitors Validated by Gaussian Accelerated Molecular Dynamics (GaMD) SimulationsSemantic proximity Read

Machine Learning-Enhanced Drug Discovery for BACE1: A Novel Approach to Alzheimer's TherapeuticsSemantic proximity Read